ENDPOINTS

Q4 earnings updates; Biogen details revised research strategy; RFK Jr. advances out of Senate committee; and more

Welcome back to Endpoints Weekly! Our team tracked fourth-quarter earnings reports from about a dozen companies this week. We’ll walk you through the highlights, including Bristol Myers Squibb’s next round of cost cuts, AstraZeneca’s pipeline ...

Feb 9, 2025 - 21:49
 0
Q4 earnings updates; Biogen details revised research strategy; RFK Jr. advances out of Senate committee; and more
Welcome back to Endpoints Weekly! Our team tracked fourth-quarter earnings reports from about a dozen companies this week. We’ll walk you through the highlights, including Bristol Myers Squibb’s next round of cost cuts, AstraZeneca’s pipeline ...
Read More

Tags:

Previous Article

AbbVie wins FDA approval for new antibiotic

Next Article

Senators ask FDA to dig into 'misleading' Super Bowl ad from Hims

Related Posts

Eli Lilly inks $630M deal for Phase 1 MASH candidate

Eli Lilly inks $630M deal for Phase 1 MASH candidate

Feb 10, 2025  0

Sanofi, AstraZeneca back Teva's call to rehear case on patent listings

Sanofi, AstraZeneca back Teva's call to rehear case on ...

Feb 9, 2025  0

Bristol Myers prunes pipeline amid new round of cost cuts

Bristol Myers prunes pipeline amid new round of cost cuts

Feb 9, 2025  0